Replies to post #151549 on Biotech Values

[DewDiligence]

WSJ profiles Claude Wischik, founder of TauRx:

http://online.wsj.com/article/SB10000872396390443624204578060941988428604.html

In the early 1990s, Dr. Wischik and his colleagues compared the postmortem brains of Alzheimer's sufferers against those of people who had died without dementia, to see how their levels of amyloid and tau differed. They found that both healthy brains and Alzheimer's brains could be filled with amyloid plaque, but only Alzheimer's brains contained aggregated tau. What's more, as the levels of aggregated tau in a brain increased, so did the severity of dementia.

The article mentions the (suspect) publication of only partial data from the phase-2 study.

[DewDiligence]

TauRx receives $112M for 20% equity stake by Genting Berhad:

http://finance.yahoo.com/news/taurx-pharmaceuticals-receives-111-8m-140100715.html

Genting is a Malaysia-based multinational conglomerate that likes to invest in new healthcare technologies—e.g. Craig Venter’s Synthetic Genomics Vaccines.

[DewDiligence]

TauRx has enrolled 300 patients in first phase-3 AD trial:

http://finance.yahoo.com/news/taurx-achieves-milestone-global-phase-184400536.html

The Phase 3 trials of a tau aggregation inhibitor target 'tau tangles' in the brain, and could provide the first definitive data on a tau-based treatment that dissolves the tangles and slows or halts Alzheimer's disease. The first study is evaluating the use of LMTX in over 800 patients with mild to moderate Alzheimer's over a 15-month treatment period. The second study is evaluating the use of LMTX in up to 700 patients with mild Alzheimer's over an 18-month treatment period.

Will they PR each increment of 100 enrolled patients?

[DewDiligence]

Tau Therapeutics is now Cavion LLC:

http://finance.yahoo.com/news/tau-therapeutics-xdynia-merge-form-120700914.html

Tau Therapeutics LLC and Xdynia LLC announced today that they have merged; the surviving entity in the merger, Tau Therapeutics LLC, has been renamed Cavion LLC.

The name “Cavion” reflects the combined company’s therapeutic approach of selectively inhibiting the Cav3 ion channel (T-type calcium channel).

[DewDiligence]

TauRx phase-3 trial in AD misses primary endpoints:

http://finance.yahoo.com/news/taurx-reports-first-phase-3-120000719.html

While the TRx-237-015 study in 891 subjects failed to meet its co-primary endpoints, clinically meaningful and statistically significant reductions in the rate of disease progression were observed across three key measures in patients who were treated with LMTX as their only Alzheimer's disease medication.